Skip to content
Loading...
Loading...
Media
Careers
Contact
en
sv
Search
Search for:
Search
Search
Search for:
Search
en
sv
Menu
en
sv
About Us
About Us
Management Team
Board of Directors
Our History
Grants
Our Science
Our Science
Pipeline
Setanaxib
Presentations & Publications
Our Products
Partnerships
Patients
Patients
Managing igA Nephropathy
Current Clinical Trials
Expanding Access to TARPEYO
Investors
Investors
Invest in Calliditas
The Share
Trading Information
Ownership Structure
Share Capital Development
Dividend Policy
Analyst Coverage
Financial Reports and Presentations
SEC Filings
Press Releases
Calendar
Investor FAQs
Contact
Governance
Governance
Corporate Governance Reports
General Meeting
Annual general meeting 2023
General Meetings
Nomination Committee
Nomination Committees
Board and Committees
Board of Directors
Board Fees
Work of the Board of Directors
Committees
Management
Management Team
Remuneration
Internal Control & Risk Management
Auditor
Articles of Association
Media
Careers
Contact
Financial Reports and Presentations
Years
All years
2023
2022
2021
2020
2019
2018
2017
Webinars
All types
Annual reports
Company presentations
Interim reports
Webinars
Webcast
November, 2023
Financial Times Event, London, November 2023
December 14, 2022
A Look into Calliditas’ China Commercial Partner Everest Medicines
November 8, 2022
KOL Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape
March 10, 2021
KOL Perspectives: The Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice
